Positive results for Amgen’s Phase 3b LIBERTY study assessing the efficacy of Aimovig
Amgen affirms optimistic outcomes for Phase 3b LIBERTY study evaluating the efficacy and safety of Aimovig (erenumab) 140 mg in patients with episodic migraine who had experienced two…
Read More...
Read More...
